Last reviewed · How we verify
NCT03181204: INVECCO
Modeling Bronchial Epithelium Modifications Associated With COPD Using iPS
trial testing Bronchial biopsy in Pulmonary Disease, Chronic Obstructive in 11 participants. Completed in 9 March 2022.
9 March 2022
Quick facts
| Lead sponsor | University Hospital, Montpellier |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 11 |
| Start date | 7 August 2017 |
| Primary completion | 9 March 2022 |
| Estimated completion | 9 March 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- Bronchial biopsy
- Skin biopsy
- Blood sample — full drug profile →
Conditions studied
- Pulmonary Disease, Chronic Obstructive — all drugs for Pulmonary Disease, Chronic Obstructive →
- Smoking — all drugs for Smoking →
Sponsor
University Hospital, Montpellier
Who can join
Adults 18 to 55, any sex, with Pulmonary Disease, Chronic Obstructive or Smoking. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to to verify the feasibility of obtaining and comparing two epithelia in two populations based on the following experiments: * Differentiation of an Induced Pluripotent Stem cell (iPS) clone derived from cutaneous biopsy in a population of heavy smokers (plus patients with chronic obstructive pulmonary disease) in order to obtain differentiated bronchial epithelia in vitro. * For each of these same patients, generation of bronchial epithelium in vitro from bronchial biopsy using human bronchial epithelial cells (HBECs) in air-liquid interface (ALI) cultures.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cell Transdifferentiation and Reprogramming in Disease Modeling: Insights into the Neuronal and Cardiac Disease Models and Current Translational Strategies.
Kalra RS, Dhanjal JK, Das M, Singh B, et al · · 2021 · cited 16× · PMID 34685537 · DOI 10.3390/cells10102558 -
The Transcriptome Landscape of the In Vitro Human Airway Epithelium Response to SARS-CoV-2.
Assou S, Ahmed E, Morichon L, Nasri A, et al · · 2023 · cited 13× · PMID 37569398 · DOI 10.3390/ijms241512017 -
Differentiation of Human Induced Pluripotent Stem Cells from Patients with Severe COPD into Functional Airway Epithelium.
Ahmed E, Fieldes M, Bourguignon C, Mianné J, et al · · 2022 · cited 10× · PMID 35954266 · DOI 10.3390/cells11152422 -
Human pluripotent stem cells for the modelling and treatment of respiratory diseases.
Goldsteen PA, Yoseif C, Dolga AM, Gosens R. · · 2021 · cited 9× · PMID 34348980 · DOI 10.1183/16000617.0042-2021 -
Human airway ex vivo models: new tools to study the airway epithelial cell response to SARS-CoV-2 infection
Assou S, Ahmed E, Morichon L, Nasri A, et al · · 2023 · DOI 10.1101/2023.04.15.536998
Verify or expand the search:
- PubMed search for NCT03181204
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bronchial biopsy
Trials testing the same drug.
- NCT02952066 — Expressions of TRPV1 in Airway of Asthmatics · NA · withdrawn
Other recruiting trials for Pulmonary Disease, Chronic Obstructive
Currently open trials in the same condition.
- NCT07177339 — eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (CO · Phase 3 · recruiting
- NCT06961214 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
- NCT06959095 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
- NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
- NCT06712563 — Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting · recruiting
Other University Hospital, Montpellier trials
Trials by the same sponsor.
- NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
- NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
- NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
- NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
- NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03181204 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
- Last refreshed: 8 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03181204.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing